Breaking News Instant updates and real-time market news.

INCY

Incyte

$97.83

3.05 (3.22%)

, MRK

Merck

$62.77

0.11 (0.18%)

08:52
10/10/16
10/10
08:52
10/10/16
08:52

Incyte treatment looking 'promising,' says JMP Securities

After reviewing recent data, JMP Securities analyst Liisa Bayko says that the combination of Incyte's (INCY) Epacadostat plus Merck's (MRK) Keytruda is "emerging as a promising treatment, potentially even best in class." The analyst says that the progression free survival rate of the combination in melanoma patients "is emerging to be quite competitive," while the efficacy rate in other solid tumors "seemed encouraging." The analyst raised her price target on Incyte to $110 from $100 and keeps an Outperform rating on the stock.

INCY

Incyte

$97.83

3.05 (3.22%)

MRK

Merck

$62.77

0.11 (0.18%)

  • 10

    Oct

  • 25

    Oct

  • 06

    Nov

INCY Incyte
$97.83

3.05 (3.22%)

10/07/16
BMOC
10/07/16
NO CHANGE
Target $121
BMOC
Outperform
Incyte price target raised to $121 from $100 at BMO Capital
BMO Capital analyst Ian Somaiya raised his price target for Incyte to $121 citing an increased probability of success for epacadostat with Keytruda in metastatic melanoma following today's data. The analyst raised his probability and success to 80% from 50% and keeps an Outperform rating on Incyte.
10/07/16
LEER
10/07/16
NO CHANGE
LEER
Outperform
Incyte Epacadostat Phase 1 Melanoma data maturing well, says Leerink
Leerink analyst Michael Schmidt says the data from ECHO-202 Phase 1 study evaluating the combination of Incyte's (INCY) IDO1 inhibitor epacadostat with Merck's (MRK) Keytruda confirms the previously published results and appears to be maturing well. The analyst reiterates an Outperform rating on Incyte's shares, saying Jakafi remains a compelling long-term growth driver for the company, expectations for baricitinib are still moderate, and its maturing oncology pipeline of 14 molecules including epacadostat represents a long-term value driver.
10/07/16
GSCO
10/07/16
NO CHANGE
GSCO
Smid-cap Biotech sector upgraded to Attractive from Neutral at Goldman
Goldman analyst Salveen Richter upgraded the Smid-cap biotechnology to Attractive and said he favors and companies with near-term pipeline data or regulatory events where he has conviction.Names he recommends are Buy rated BioMarin (BMRN), bluebird bio (BLUE), GW Pharma (GWPH), Incyte (INCY), Kite (KITE), and Sage (SAGE).
10/06/16
LEHM
10/06/16
DOWNGRADE
Target $50
LEHM
Equal Weight
Alnylam downgraded to Equal Weight from Overweight at Barclays
Barclays analyst Geoff Meacham downgraded Alnylam Pharmaceuticals (ALNY) to Equal Weight saying he views other SMid cap biotech names as more attractive following the company's recent pipeline setbacks. The analyst removed Revusiran sales from his Alnylam model after the program was discontinued yesterday and he cut his price target for the shares to $50 from $85. Meacham lists Neurocrine (NBIX), Prothena (PTRA) and Incyte (INCY) as names he finds more attractive over the next 12 months. Alnylam is trading down 44% in pre-market trading to $39.25.
MRK Merck
$62.77

0.11 (0.18%)

10/10/16
LEER
10/10/16
NO CHANGE
LEER
Market Perform
Merck 'steals the show' at ESMO with Keytruda data, says Leerink
Leerink analyst Seamus Fernandez said Merck (MRK) stole the show at ESMO with its Keytruda data and he continues to think the company will dominate first line lung cancer treatment for years to come in patients with 50%+ PDL1 expression. Additionally, he expects Merck to gain additional traction in the overall market, noting that confirmation that Keytruda is benefiting patients when combined with Alimta/carboplatin with Alimta maintenance raises the possibility Merck could compete broadly in the overall non-squamous patient population. However, Fernandez keeps a Market Perform rating on Merck, as he thinks its current valuation largely reflects improved growth prospects through 2020.
10/10/16
BMOC
10/10/16
NO CHANGE
BMOC
Merck should strengthen leadership in first line NSCLC, says BMO Capital
BMO Capital analyst Alex Arfaei says that upcoming data should strengthen Merck's (MRK) lead in 1L NSCLC. The analyst adds that the data could support off-label use of Merck's Keytruda in additional 1L NSCLC patients, and he says that the data "should be negative" for Bristol-Myers' (BMY) Opdivo drug. Arfaei keeps an Outperform rating on Merck and a Market Perform rating on Bristol-Myers.
10/10/16
LEER
10/10/16
NO CHANGE
LEER
Outperform
Leerink sees Bristol-Myers sliding after Merck's 'spectacular' Keytruda data
Leerink analyst Seamus Fernandez said Bristol-Myers' (BMY) Checkmate-026 data presented at the European Society of Medical Oncology meeting was disappointing, noting there was no signal of benefit on progression-free survival or overall survival and only "modest differentiation" on response rate in the 88 patients with PDL1 biomarker positivity greater than or equal to 50%. Meanwhile, Merck (MRK) presented "spectacular" data for Keytruda monotherapy at the meeting, said Fernandez, who expects Bristol shares to be down "significantly" today in light of the meeting presentations. The analyst, who still thinks Bristol has a significant opportunity to compete with Merck's Keytruda in the PDL1 high portion of the market, keeps an Outperform rating on Bristol shares, which are down nearly 6% in pre-market trading.

TODAY'S FREE FLY STORIES

VNCE

Vince Holding

$4.55

0.35 (8.33%)

20:25
12/07/16
12/07
20:25
12/07/16
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 09

    Jan

NWBO

Northwest Biotherapeutics

$0.55

0.0227 (4.33%)

20:17
12/07/16
12/07
20:17
12/07/16
20:17
Hot Stocks
Northwest Biotherapeutics to delist from Nasdaq, confirms clinical trial plans »

Northwest Biotherapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$111.03

1.08 (0.98%)

, MSFT

Microsoft

$61.37

1.42 (2.37%)

20:07
12/07/16
12/07
20:07
12/07/16
20:07
Periodicals
NHL in negotiations to bring Apple devices to team benches, TSN says »

The NHL has told teams it…

AAPL

Apple

$111.03

1.08 (0.98%)

MSFT

Microsoft

$61.37

1.42 (2.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 13

    Mar

ATKR

Atkore

$19.71

-0.11 (-0.55%)

19:59
12/07/16
12/07
19:59
12/07/16
19:59
Syndicate
Atkore 8M share Secondary priced at $19.00 »

Credit Suisse, Deutsche…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

BPMC

Blueprint Medicines

$26.20

-2.23 (-7.84%)

19:58
12/07/16
12/07
19:58
12/07/16
19:58
Syndicate
Blueprint Medicines 5M share Secondary priced at $25.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

LULU

lululemon

$59.84

2.6 (4.54%)

19:50
12/07/16
12/07
19:50
12/07/16
19:50
Hot Stocks
lululemon CFO says early Q4 trends strengthened into December »

Speaking during the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 09

    Jan

LULU

lululemon

$59.84

2.6 (4.54%)

19:50
12/07/16
12/07
19:50
12/07/16
19:50
Hot Stocks
lululemon CEO highlights Q3 gross margin, reports 11% comp growth in pants »

Speaking during the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 09

    Jan

CVX

Chevron

$114.44

1.68 (1.49%)

19:20
12/07/16
12/07
19:20
12/07/16
19:20
Hot Stocks
Chevron announces $19.8B capital, exploratory budget for 2017 »

Chevron announced a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

X

U.S. Steel

$37.49

1.54 (4.28%)

18:49
12/07/16
12/07
18:49
12/07/16
18:49
Periodicals
U.S. Steel CEO: Company may bring back 10,000 U.S. jobs, CNBC says »

U.S. Steel could bring…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VNDA

Vanda

$15.40

-0.6 (-3.75%)

18:47
12/07/16
12/07
18:47
12/07/16
18:47
Hot Stocks
Vanda settles Fanapt patent litigation with Apotex »

Vanda Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AE

Adams Resources

$42.31

-0.68 (-1.58%)

, SWN

Southwestern Energy

$12.37

-0.08 (-0.64%)

18:46
12/07/16
12/07
18:46
12/07/16
18:46
Hot Stocks
Adams Resources appoints Josh Anders as CFO »

Adams Resources &…

AE

Adams Resources

$42.31

-0.68 (-1.58%)

SWN

Southwestern Energy

$12.37

-0.08 (-0.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EZPW

EZCORP

$11.80

0.05 (0.43%)

18:42
12/07/16
12/07
18:42
12/07/16
18:42
Earnings
EZCORP reports Q4 EPS with items (31c), may not compare to consensus 6c »

EPS figure includes…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

RICE

Rice Energy

$24.59

-0.16 (-0.65%)

18:33
12/07/16
12/07
18:33
12/07/16
18:33
Initiation
Rice Energy initiated  »

Rice Energy initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$770.42

5.7 (0.75%)

18:30
12/07/16
12/07
18:30
12/07/16
18:30
Periodicals
Amazon spokesperson denies 2,000 grocery stores report, CNET says »

Following a report by the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ICON

Iconix Brand

$9.26

0.14 (1.54%)

18:23
12/07/16
12/07
18:23
12/07/16
18:23
Hot Stocks
Iconix Brand reports employment termination of Chief Strategy Officer Blumberg »

Iconix Brand disclosed in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PBYI

Puma Biotechnology

$39.80

-2 (-4.78%)

18:23
12/07/16
12/07
18:23
12/07/16
18:23
Hot Stocks
Puma Biotechnology 'pleased' to complete biomarker analysis of neratinib »

Puma Biotechnology…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FTK

Flotek

$11.10

-2.01 (-15.33%)

18:17
12/07/16
12/07
18:17
12/07/16
18:17
Hot Stocks
Flotek: Reviewing FourWorld Capital short report, remain confident in product »

Speaking earlier during…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 07

    Dec

PBYI

Puma Biotechnology

$39.80

-2 (-4.78%)

18:09
12/07/16
12/07
18:09
12/07/16
18:09
Hot Stocks
Puma Biotechnology 'pleased' with preliminary neratinib activity »

Puma Biotechnology…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PNM

PNM Resources

$32.05

0.45 (1.42%)

18:09
12/07/16
12/07
18:09
12/07/16
18:09
Hot Stocks
PNM Resources requests an electric rate increase of $99M in New Mexico »

PNM Resources' New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

BK

BNY Mellon

$48.55

0.56 (1.17%)

18:03
12/07/16
12/07
18:03
12/07/16
18:03
Periodicals
BNY Mellon outage led to certain Swift payment failures, WSJ reports »

Bank of New York Mellon…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TLRD

Tailored Brands

$18.93

0.62 (3.39%)

17:52
12/07/16
12/07
17:52
12/07/16
17:52
Hot Stocks
Tailored Brands up 22% to $23.20 after Q3 results beat estimates »

The company also raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

FLXS

Flexsteel Industries

$59.12

2.92 (5.20%)

, UNH

UnitedHealth

$159.40

2.08 (1.32%)

17:50
12/07/16
12/07
17:50
12/07/16
17:50
Hot Stocks
Flexsteel names Eric Rangen chair of the board »

Flexsteel Industries…

FLXS

Flexsteel Industries

$59.12

2.92 (5.20%)

UNH

UnitedHealth

$159.40

2.08 (1.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NKE

Nike

$52.10

1.53 (3.03%)

, UA

Under Armour

$27.03

1.62 (6.38%)

17:49
12/07/16
12/07
17:49
12/07/16
17:49
Periodicals
Nike losing market share to faster-growing rivals, Barron's reports »

Despite being down nearly…

NKE

Nike

$52.10

1.53 (3.03%)

UA

Under Armour

$27.03

1.62 (6.38%)

ADDYY

adidas

$76.96

1.225 (1.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Dec

T

AT&T

$40.45

1.1 (2.80%)

17:45
12/07/16
12/07
17:45
12/07/16
17:45
Conference/Events
AT&T management to meet with Jefferies »

Group dinner to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 07

    Dec

  • 07

    Dec

EFC

Ellington Financial

$16.30

0.2 (1.24%)

17:41
12/07/16
12/07
17:41
12/07/16
17:41
Hot Stocks
Ellington Financial reports estimated book value per share $19.80 as of Nov 30 »

Ellington Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.